Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy

por Young, Katherine G., Hopkins, Rhian, Shields, Beverley M., Thomas, Nicholas J., McGovern, Andrew P., Dennis, John M.
Publicado 2023

Correction to: The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis

por Young, Katherine G., McGovern, Andrew P., Barroso, Inês, Hattersley, Andrew T., Jones, Angus G., Shields, Beverley M., Thomas, Nicholas J., Dennis, John M.
Publicado 2023

The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis

por Young, Katherine G., McGovern, Andrew P., Barroso, Inês, Hattersley, Andrew T., Jones, Angus G., Shields, Beverley M., Thomas, Nicholas J., Dennis, John M.
Publicado 2022

Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors

por Young, Katherine G, McInnes, Eram Haider, Massey, Robert J, Kahkohska, Anna R, Pilla, Scott J, Raghaven, Sridharan, Stanislawski, Maggie A, Tobias, Deirdre K, McGovern, Andrew P, Dawed, Adem Y, Jones, Angus G, Pearson, Ewan R, Dennis, John M
Publicado 2023

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review

por Young, Katherine G., McInnes, Eram Haider, Massey, Robert J., Kahkoska, Anna R., Pilla, Scott J., Raghavan, Sridharan, Stanislawski, Maggie A., Tobias, Deirdre K., McGovern, Andrew P., Dawed, Adem Y., Jones, Angus G., Pearson, Ewan R., Dennis, John M.
Publicado 2023